• This Christmas, give your loved ones financial intelligence. Buy two copies of Value.able for the price of one this Christmas. Discount code: XMAS24 BUY NOW

Sirtex Medical – a step change from 2015?

Sirtex Medical – a step change from 2015?

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Andrew Kennedy was interviewed on his thoughts regarding the application of Sirtex Medical’s SIR-Spheres microspheres.

Dr Kennedy, who is Physician in Chief of Radiation Oncology at Sarah Cannon Research Institute in Nashville, Tennessee made the following points:

 

  1. “I know it works wonderfully for a lot of patients… The frustration over the years has been that patients I know would benefit weren’t being offered this treatment”.  Often, patients were cared for by physicians that have insufficient knowledge or understanding of the procedure.
  2. The low toxicity of the technique – citing his experience with patients who have virtually no side effects from the treatment at around 90 per cent. “For those that do have side effects, it is generally fatigue, lasting 3 to 5 days after the procedure; a few will have pain and a few more will have some nausea”.
  3. “I am getting very excited that it’s getting more and more accessible”. Results from the SIRFLOX study (NCT00724503) are expected to be available early next year and presented at the next ASCO Annual Meeting in June 2015.

Watch Dr Kennedy’s explanation of SIR-Spheres, below.

 

INVEST WITH MONTGOMERY

Chief Executive Officer of Montgomery Investment Management, David Buckland has over 30 years of industry experience. David is a deeply knowledgeable and highly experienced financial services executive. Prior to joining Montgomery in 2012, David was CEO and Executive Director of Hunter Hall for 11 years, as well as a Director at JP Morgan in Sydney and London for eight years.

This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.

Why every investor should read Roger’s book VALUE.ABLE

NOW FOR JUST $49.95

find out more

SUBSCRIBERS RECEIVE 20% OFF WHEN THEY SIGN UP


2 Comments

  1. grant.westcott.7
    :

    This has been a great investment for me but, more importantly, knowing as we do, people who are no longer with us because this treatment was not available I am thrilled to see an Australian company come up with a life changing and life saving product like this. It makes a simple finance professional humble knowing how many very clever people make a difference through their life changing work. Personally we support the Malaghan Institute in Wellington which is doing wonderful work in the field of cancer research through the immune system. If you have not heard of them and are interested you can get a snapshot of their work here: http://www.malaghan.org.nz.

    Thanks to all the Montgomery team for the interesting and insightful articles and videos.

    Kind regards
    Grant W

Post your comments